The role of nicotinic acid metabolites in flushing and hepatotoxicity

Journal of Clinical Lipidology

Volumn 1, Issue 3, 2007, Pages 191-193

  Stern, Ralph H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Flushing; Hepatotoxicity; Metabolites; Nicotinamide; Nicotinic acid; Nicotinuric acid

Indexed keywords

ACETYLSALICYLIC ACID; NICOTINAMIDE; NICOTINIC ACID; NICOTINURIC ACID; PROSTAGLANDIN; PROSTAGLANDIN D2;

CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; HUMAN; LANGERHANS CELL; LIVER TOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 34447308755     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.04.003     Document Type: Review

References (15)

1. McCormack P.L., and Keating G.M. Prolonged-release nicotinic acid a review of its use in the treatment of dyslipidaemia. Drugs 65 (2005) 2719-2740
2. Jones K.M. The mechanism of nicotinuric acid synthesis. Biochem J 73 (1959) 714-719
3. Magni G., Amici A., Emanuelli M., Orsomando G., Raffaelli N., and Ruggieri S. Enzymology of NAD+ homeostasis in man. Cell Mol Life Sci 61 (2004) 19-34
4. Piepho R.W. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 86 (2000) 35L-40L
5. Fossler M. WN Analysis of IR and ER NUA data. FDA memorandum dated June 17, 1997. Available under Freedom of Information Act.
6. Fossler M.J. A pharmacokinetic/pharmacodynamic model of the vasodilatory effects of niacin. Clin Pharmacol Ther 63 (1998) 161
7. Ding R.W., Kolbe K., Merz B., et al. Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther 46 (1989) 642-647
8. 2 in human macrophages: An in vitro model of the niacin flush. Atherosclerosis 192 (2006) 253-258
9. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharm Sci 27 (2006) 384-390
10. Benyo Z., Gille A., Kero J., et al. GPR 109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 115 (2005) 3634-3640
11. Benyo Z., Gille A., Benett C., Clausen B.E., and Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharm 70 (2006) 1844-1849
12. 2 in response to nicotinic acid. J Invest Dermatol 126 (2006) 2637-2646
13. Wise A., Foord S.M., Fraser N.J., et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278 (2003) 9869-9874
14. 2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38 (1989) 263-274
15. Stern R.H., Freeman D., and Spence J.D. Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action?. Metabolism 41 (1992) 879-881